EPIK Biosciences Launches to Pioneer Ketamine-Powered Psychedelic Therapies to Transform Treatment of Mental Health, Pain, and Addiction 

EPIK Biosciences, a psychedelic drug development company, has announced its formation. The company aims to develop synergistic combination medications and advanced co-delivery formulations targeting mental health disorders, severe/chronic pain, and substance use disorders. 

Strategic alliances, partnerships between biotechnology firms and healthcare providers, are increasing, leading to more innovative treatments and therapies. The state-level access programs are surging, FDA “Breakthrough Therapy” designations are accelerating, and institutional capital is flowing into the sector. 

According to Towards Healthcare, the psychedelic drugs market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 6.68 billion in 2026 to approximately USD 23.14 billion by 2035, representing a compound annual growth rate (CAGR) of 14.8% from 2026 to 2035. Growth is driven by the increasing prevalence of mental health disorders, a rise in cases of depression, anxiety, PTSD, and other mental health issues, which has created a significant unmet need for treatment. Regulatory approvals for medical applications of psychedelics are a major growth driver.  

About EPIK Biosciences 

The Company has initiated preclinical pharmacokinetic and animal studies across its lead formulations and is concurrently building an intellectual property portfolio covering its compositions, delivery technologies, and methods of use. EPIK Biosciences is also developing a portfolio of proprietary ketamine-based formulations engineered around NMDA receptor modulation to improve on the efficacy, durability, and accessibility limitations of currently available treatments. 

EPIK is working with Casimir Jones, S.C., a life sciences intellectual property firm and recognized leader in psychedelic patent law, to advise the Company on its patent strategy and support the advancement of its drug formulations through preclinical and clinical development toward FDA approval. 

A recent report by Towards Healthcare highlights that the psychedelic drugs market is witnessing growth due to the company's innovative approach to developing ketamine-based therapies, which offer a unique opportunity in the market. With its focus on mental health, pain, and addiction, EPIK Biosciences aims to provide a more accessible and effective treatment option for patients. It presents a promising opportunity for investors and entrepreneurs looking to capitalize on the growing demand for innovative biotechnology solutions.